Divine Aleru, Microbiome Signatures Research Coordinator

This study identifies bacterial vaginosis-associated species, improving BV diagnostics and treatment strategies through metagenomic sequencing.

This review evaluates the use of tinidazole in treating bacterial vaginosis, highlighting its efficacy, favorable pharmacokinetics, and reduced side effects compared to metronidazole, especially for recurrent cases.

This review examines how polymicrobial biofilms contribute to bacterial vaginosis (BV) treatment failure and explores alternative strategies for improved therapy.

This study analyzed vaginal microbiota diversity in women with BV using molecular techniques. It identified key BV-associated bacteria and emphasized the need for molecular diagnostics and microbiome-targeted therapies.

This study analyzed daily changes in vaginal microbiota before, during, and after BV episodes. Findings highlight microbial instability, early dysbiosis markers, and the need for microbiome-focused BV treatments.

This meta-analysis compared BV treatments, identifying ornidazole as the most effective oral drug and sucrose/probiotics as top non-antibiotic options. Restoring Lactobacillus dominance is key, with vaginal probiotics and sucrose showing high cure rates.

A nutrient-rich diet lowers bacterial vaginosis (BV) risk, while processed foods increase it. This study highlights the importance of dietary choices in vaginal microbiome balance, offering insights for clinicians on how diet influences BV risk.

Higher dietary fat intake increases the risk of bacterial vaginosis (BV), while folate, vitamin E, and calcium may lower severe BV risk. This study suggests dietary interventions could play a role in managing BV, offering insights for clinicians on how nutrition affects vaginal microbiome balance.

This review reveals high BV recurrence rates after metronidazole or clindamycin treatment due to microbial biofilms and potential sexual transmission. While both antibiotics show similar short-term efficacy, they differ in resistance patterns. Biofilm disruptors and partner treatment may improve outcomes, but better diagnostics and combination therapies are urgently needed.

This review explores the antimicrobial potential of essential oils (EOs) in combating microbial biofilms, highlighting their effectiveness against pathogens like S. aureus and C. albicans. EOs can serve as an alternative or adjunct to conventional antibiotics, particularly in medical device infections.

This study identifies DAHP synthase as a promising drug target for Gardnerella vaginalis in the treatment of bacterial vaginosis, presenting potential inhibitors with favorable pharmacokinetics.

This study identifies phospho-2-dehydro-3-deoxyheptonate aldolase as a drug target in Gardnerella vaginalis and highlights five FDA-approved compounds as potential treatments for bacterial vaginosis.

This study explores the link between vaginal microbiota and recurrent spontaneous abortion (RSA), showing that drug treatment, including metformin combined with aspirin, can alter microbiota composition and potentially improve pregnancy outcomes by increasing Lactobacillus abundance.

CBD shows antibacterial and antibiofilm activity against Gardnerella vaginalis, suggesting its potential as a novel treatment for bacterial vaginosis, particularly in biofilm-related infections.

Boric acid offers promising results for treating resistant vulvovaginal candidiasis, bacterial vaginosis, and trichomoniasis. It shows comparable efficacy to oral itraconazole, with fewer adverse events.

This review explores bacterial vaginosis (BV), emphasizing microbial shifts, diagnostic challenges, and treatment strategies. It highlights the role of biofilms, emerging molecular diagnostics, and microbiome-based therapies like probiotics and vaginal microbiota transplantation, advocating for more effective, microbiome-informed approaches to managing BV and its recurrence.

This review explores bacterial vaginosis diagnostics, highlighting traditional limitations and emerging molecular solutions. Advances in sequencing, metabolomics, and AI-driven analysis offer promising improvements, enhancing diagnostic accuracy and treatment strategies.

This review explores bacterial vaginosis recurrence, emphasizing microbial persistence, reinfection, and partner treatment. It highlights the need for improved therapeutic strategies, including antimicrobial and microbiome-focused approaches, to reduce recurrence and improve long-term cure rates.

This review discusses bacterial vaginosis, biofilm formation, and emerging therapies targeting biofilms for more effective BV treatments.

BV disrupts Lactobacillus dominance, increasing infertility risk via inflammation, PID, and endometritis. L. crispatus probiotics reduce BV recurrence; CE treatment boosts IVF success. Early screening and microbiome-targeted therapies are vital to prevent reproductive complications.

Study links BV and past chlamydial infection to tubal infertility, with 87.5% of BV-positive women having tubal damage. Both infections were often asymptomatic. IVF pregnancy rates were unaffected, but BV showed lower implantation trends. Findings highlight BV’s role in infertility, urging early screening to prevent tubal damage.

This review links BV recurrence to resilient biofilms formed by Gardnerella vaginalis. Probiotics and biofilm disruptors (e.g., Astodrimer gel) improve outcomes by restoring Lactobacillus dominance. Current antibiotics fail to penetrate biofilms, necessitating multimodal therapies. Future research should explore VMT and microbiome-targeted interventions for sustained BV remission.

This review explores bacterial vaginosis, emphasizing its recurrence, microbial associations, and treatment challenges. It highlights the need for microbiome-based therapies, standardized diagnostic criteria, and potential partner treatment to reduce reinfection. The findings underscore the importance of improved strategies for long-term BV management.

This study used high-resolution sequencing to analyze bacterial communities in women with BV. Findings reveal distinct microbial associations, diagnostic inconsistencies, and racial differences in BV prevalence, highlighting the need for microbiome-targeted therapies and improved diagnostic tools.